Table 1.

MSC-therapeutic products for the treatment of various diseases

MSC product name	Company	Approved Country	Year	Indication	Cell source	Route	Frequency	Dose
Hearticellgram-AMI	Pharmicell Co. Ltd.	South Korea	2011	Acute myocardial infarction	Autologous BM	Coronary arterial injection	Single injection; Readministration may be considered	weight 60 kg or less: 10 ml/5 × 107 cells; 61–80 kg: 14 ml/7 × 107 cells; 81 kg or more: 18 ml/9 × 109 cells
Cartistem	Medipost Co. Ltd.	South Korea	2012	Knee articular cartilage defects	Allogeneic UC	Local administration (surgical area)	Single injection; Readministration may be considered	2.5 × 106 cells/500 μL/cm2 (size of knee cartilage defects)
Cupistem	Anterogen Co. Ltd.	South Korea	2012	Crohn’s fistula	Autologous BM	Local administration (surgical area)	Single injection; Readministration may be considered	1 × 107 cells/cm2 of the fistula surface area
Prochymal	Osiris Therapeutics Inc., Mesoblast Ltd.	Canada	2012	GVHD	Allogeneic BM	i.v.	Twice, weekly	108 unit/15 mL
Neuronata-R	Corestem Inc.	South Korea	2014	Amyotrophic lateral sclerosis	Autologous BM	Intrathecal injection	Twice, monthly	4.0 × 107 cells/4 mL
Temcell HS	JCR Pharmaceuticals	Japan	2015	GVHD	Allogeneic BM	i.v.	Twice a week for 4 weeks	2 × 106 cells/kg body weight/18 mL
Stempeucel	Stempeutics Research PVT	India	2016	OA	Allogeneic BM	Intra-articular injection	Single injection; Readministration may be considered	25–150 million cells
Stempeucel	Stempeutics Research PVT	India	2016	Critical limb ischemia	Allogeneic BM	Intramuscular injection	Single injection; Readministration may be considered	200–400 million cells
Alofisel	TiGenix NV/Takeda	European Union	2018	Complex perianal fistulas in Crohn’s disease	Allogeneic Adipose	50% into the fistula walls, and the remaining into the surrounding tissue	Single injection; Readministration may be considered	120 million cells
Stemirac	Nipro Corp	Japan	2018	Spinal cord injury	Autologous BM	i.v.	Single injection; Readministration may be considered	50–200 million cells within 3–8 weeks after the injury
Mesestrocell	Cell Tech Pharmed	Iran	2018	OA	Allogeneic BM	Intra-articular injection	Single injection	2 × 107 cells/knee
Vartocell	Cell Tech Pharmed	Iran	2020	Spastic cerebral palsy	Allogeneic UC	Intrathecal and intracoronary injection	N.A.	2 × 107 cells
Akuugo	SanBio Co., Ltd.	Japan	2024	Chronic motor paralysis caused by traumatic brain injury	Allogeneic BM	Intralesional injection	Single injection	5 × 106 cells
Ryoncil	Mesoblast	USA	2024	SR-aGVHD	Allogeneic BM	i.v.	Twice a week for 4 consecutive weeks	2 × 106 cells/kg
Aimmexitocel	Platinum Life	China	2025	SR-aGVHD	Allogeneic UC	i.v.	Twice a week for 4 or 8 consecutive weeks	1 × 106 cells/kg

i.v. intravenous, BM bone marrow, UC umbilical cord, GVHD graft-versus-host disease, OA osteoarthritis, SR-aGVHD steroid-resistant acute graft-versus-host disease, N.A. not applicable